Survival benefit and safety of the combinations of FOLFOXIRI &plusmn; bevacizumab versus the combinations of FOLFIRI &plusmn; bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis

Original Research

Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis

Total article views		HTML views	PDF downloads	Totals
8,631	Dovepress*	7,510+	1,181	8,691
	PubMed Central*	1,121	422	1,543
	Totals	8,631	1,603	10,234
*Since 4 August 2016